Literature DB >> 23103103

[Clinical factors associated with invasive pulmonary aspergillosis in patients with chronic pneumopathies and respiratory isolation of Aspergillus spp].

Juan José Castón1, María José Linares, Antonio Rivero, Manuel Casal, Julián Torre-Cisneros.   

Abstract

BACKGROUND AND OBJETIVE: To determine clinical variables to distinguish invasive pulmonary aspergillosis (IPA) from colonization in patients with chronic pneumopathies with positive culture of Aspergillus spp. in respiratory samples. PATIENTS AND METHODS: Retrospective cohort study including patients with respiratory isolations of Aspergillus spp. during a period of 10 years. IPA was evaluated according to the Bulpa criteria. Clinical variables were collected and a multiple logistic regression analysis was carried out.
RESULTS: Eighty-three patients with isolation of Aspergillus spp. from respiratory samples were included; 68.7% (n=57) of the patients had chronic obstructive pulmonary disease, 18% (n=15) pulmonary fibrosis and 13.3% (n=11) bronchial asthma. Twenty-two patients (26.6%) had IPA. The use of fluconazole (OR 4.49; CI 95% 1.5-13.4; P=.007), severe respiratory failure (OR 4.64; CI 95% 1.46-14.72; P=.009) and hospitalization time (OR 1.05; CI 95% 1.01-1.1; P=.006) were associated with IPA.
CONCLUSIONS: Prior use of fluconazole, severe respiratory failure and hospitalization time are associated with IPA in patients with chronic pneumopathies with respiratory isolation of Aspergillus spp.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23103103     DOI: 10.1016/j.medcli.2012.07.021

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  Development of Aspergillosis in a cohort of non-neutropenic, non-transplant patients colonised by Aspergillus spp.

Authors:  José Barberán; Francisco-Javier García-Pérez; Victoria Villena; Alberto Fernández-Villar; Eduardo Malmierca; Cristina Salas; María-José Giménez; Juan-José Granizo; Lorenzo Aguilar
Journal:  BMC Infect Dis       Date:  2017-01-06       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.